Who Owns Immunocore Company?

Immunocore Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Immunocore today?

Immunocore, founded in 2008 in Oxfordshire, went public on Nasdaq in February 2021 and commercialized KIMMTRAK, making it a rare TCR-platform biotech with commercial revenue.

Ownership mixes founders/insiders, legacy venture funds, strategic partners and growing US institutional/index holders; 2024 product revenue exceeded $300 million, and major holders influence board and strategy. See Immunocore Porter's Five Forces Analysis

Founders and early ownership of Immunocore trace to its 2008 formation, when leading T‑cell receptor (TCR) scientists and university clinical leaders engineered the ImmTAC platform and retained control through seed funding rounds.

Scientific founding team

Co-founded in 2008 by Sir John Bell and Bent Jakobsen, PhD, alongside technical leads from the Avidex/MediGene/Adaptimmune lineage who provided core TCR expertise.

Early equity concentration

Equity was concentrated among scientific founders and seed backers who funded the TCR platform's spin‑out into an independent company.

Founders' vesting

Founders were subject to standard UK venture vesting: 4‑year schedules with 1‑year cliffs, IP assignment and reverse‑vesting protections.

Jakobsen's role

Bent Jakobsen acted as the primary scientific equity holder and first CSO/CEO‑level scientific leader for the ImmTAC modality.

Sir John Bell's influence

Sir John Bell provided scientific architecture and early chair‑level influence, holding a minority but material stake at formation.

Recruitment and option pool

Early option pools of 10–15% were created to attract TCR engineering, translational oncology, and manufacturing talent.

Seed capital came from angel and specialist UK/EU biotech investors; founders collectively controlled the company pre‑Series A, with governance stabilized via investor rights, protective provisions and ROFR/buy‑sell clauses common in UK term sheets.

Key facts on founders and early ownership

Core ownership details, governance and early investor arrangements that shaped Immunocore's initial corporate structure.

• Bent Jakobsen: primary scientific equity holder and first CSO/CEO‑level scientific leader
• Sir John Bell: scientific architect and early chair‑level influence with a material minority stake
• Founders subject to 4‑year vesting with 1‑year cliffs; IP assignment and reverse‑vesting standard
• Early option pool sized at 10–15% to hire technical and translational teams

For details on later ownership transitions, institutional shareholders and public‑market developments see the article: Marketing Strategy of Immunocore

Immunocore SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key financings, a 2021 Nasdaq IPO and KIMMTRAK commercialisation transformed Immunocore’s ownership from founder/VC control to a broadly held public company, shifting governance and strategic priorities toward institutional investors and commercial execution.

Current (2024–2025) major stakeholders reflect a shift to institutional ownership, with aggregate public/institutional holdings dominating the shareholder register and legacy VCs and insiders holding reduced, often single-digit positions.

Major stakeholder snapshot (approx., 2024–2025)

Public and institutional ownership now exceeds 70%, changing strategic emphasis toward commercial delivery and capital efficiency.

• Top institutional holders frequently include BlackRock, Vanguard and Wellington, collectively often representing 15–25% by quarter‑end filings
• Healthcare specialist investors observed: Orbimed, RA Capital, Baker Brothers, T. Rowe Price, Fidelity
• Legacy European biotech VCs and strategic collaborators generally hold sub‑10% stakes individually after secondaries
• Founders and insiders retain single‑digit ownership via options/RSUs and residual shares

Institutional concentration influences board composition, proxy‑advisory alignment and priorities—commercial execution of KIMMTRAK and pipeline catalysts (PRAME, HPV, HBV programs) are primary value drivers for Immunocore shareholders; see a concise company background at Brief History of Immunocore.

Immunocore PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of mid-2025 the board of directors at Immunocore plc comprises independent biopharma leaders, scientific founders/representatives and investor-affiliated directors, with committee chairs drawn from independent members and commercial oncology and immunology expertise represented among directors.

The board structure reflects standard governance for a UK-domiciled plc listed in the US, with one-share-one-vote ordinary shares and UK Companies Act compliance alongside US 20-F and 6-K disclosures; recent governance votes have received typical large-cap biotech institutional support and no public proxy battles or activist campaigns were reported through 2024–2025.

Board composition and voting

Independent committee chairs, founder scientific presence, and declining investor-designated director counts characterize the board; voting uses one-share-one-vote ordinary shares.

• One-share-one-vote ordinary shares; no dual-class or golden shares
• Independent chairs for audit, compensation, nominating committees
• At least one director with deep immunology and one with commercial oncology expertise
• Investor-designees declined as ownership dispersed; founder-scientist roles remain advisory

For context on strategy linked to ownership and governance, see Growth Strategy of Immunocore.

Immunocore Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent changes in Immunocore ownership show rising institutional and passive investor presence as KIMMTRAK revenue exceeded £/€/$300,000,000 in 2024 and guidance pointed to sustained double‑digit growth, while legacy venture holders have used marketed secondaries to modestly increase free float.

Capital strategy relies on product revenue and selective partnerships, with no large buybacks reported and limited near‑term equity needs unless major BD transactions occur; industry consolidation and activist interest in late‑stage oncology increase strategic scrutiny, though no major activism has emerged for the company.

Institutional and Passive Inflows

Institutional ownership climbed as KIMMTRAK sales surpassed 300 million in 2024, increasing ETF and index inclusion and shifting the shareholder base toward US long‑only investors.

Secondary Market Activity

Marketed secondaries by legacy venture holders have modestly increased free float without issuing new primary shares, improving liquidity for new institutional entrants.

Equity Incentives and Dilution

Annual option and RSU programs maintain an overhang typically in the low‑teens percent of shares outstanding, causing incremental dilution while aligning executive and commercial teams with shareholders.

Strategic Partnership Potential

Analysts note potential ex‑US co‑commercial arrangements or equity‑linked deals for next‑wave TCR programs that could alter ownership via partnership equity or convertible instruments.

Outlook: shareholder mix likely to continue shifting to passive and institutional holders as market cap and liquidity grow; governance remains one‑share‑one‑vote with no signs of dual‑class adoption or privatization, and independent oversight continues to be emphasized. Read more on market positioning in Competitors Landscape of Immunocore

Immunocore Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔